MEDICAL COLLEGE OF WISCONSIN

The phase 3 ECOG-ACRIN EA4151 trial is investigating whether autologous hematopoietic cell transplantation (auto-HCT) still benefits mantle cell lymphoma patients in the era of improved first-line therapies.

A phase I/II study of adaptive manufactured lentiviral anti-CD20/anti-CD19 CAR T-cells demonstrated a 100% response rate with 88% complete responses in relapsed/refractory mantle cell lymphoma patients.

A qualitative study at a San Francisco safety-net hospital uncovered six interconnected themes characterizing Latine patients' experiences with psoriasis management and treatment decisions.

A phase III trial (EA4151) found that autologous stem cell transplantation (ASCT) did not improve overall survival in MCL patients with undetectable measurable residual disease (MRD) after initial treatment.

Zamto-cel, a tandem CD20/CD19 CAR T-cell therapy, demonstrated a 72.8% overall response rate and a 50.8% complete remission rate in r/r DLBCL patients.

• The PARSIFAL trial indicated no significant efficacy difference between palbociclib combined with fulvestrant versus letrozole, suggesting current practices of using CDK4/6 inhibitors with aromatase inhibitors remain valid. • Young-PEARL data supports using palbociclib plus an aromatase inhibitor and ovarian suppression over chemotherapy in premenopausal patients with ER-positive, HER2-negative metastatic breast cancer after tamoxifen progression. • Clinicians should carefully interpret adverse event data, as seen in Young-PEARL, where higher grade 3 adverse events in the palbociclib arm were mainly manageable asymptomatic neutropenia. • Ongoing research explores cemiplimab, a PD-1 inhibitor, in combination with standard chemotherapy for triple-negative and ER-positive/HER2-negative breast cancer, expanding eligibility to include PD-L2-positive patients.

Cilta-cel demonstrates significant survival benefits in multiple myeloma patients, even in late and early relapse scenarios.

The CHEST 2024 annual meeting gathered 6,000-8,000 pulmonology experts, highlighting significant advances in Pulmonary Embolism Response Teams (PERT) and personalized treatment approaches.

A new CAST regimen, combining post-transplant cyclophosphamide, abatacept, and tacrolimus, shows promise in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (HSCT).

The Medical College of Wisconsin (MCW) Cancer Center is piloting OncoLLM, an AI platform, to automate and improve patient-trial matching, potentially enhancing access to clinical trials.